secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2024-07-23T23:59:59+00:00
Accession:  0001213900-24-063627
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma CFO suspends work amid salary dispute; company corrects license fee numbers downward
--------------------------------------------------------------------------------

- CFO Leeds Chow suspends work due to disagreements over salary owed; CEO Uttam Patil becomes interim CFO.
- Potential aggregate license fee corrected from $24M to $19M in prior press release.
- Total possible cash payment from licensees corrected from $23.7M to $18.7M.
- Disagreement limited to salary; not related to public filings disclosures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024063627/0001213900-24-063627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024063627/ea020990501-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-063627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer